You are here

Rosa & Co. Announces Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd.

SAN CARLOS, Calif. and TOKYO, March 12, 2019 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm known worldwide for its PhysioPD™ Research Platforms, today announced the initiation of a long-term Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd. to provide Rosa's PhysioPD research services.

The collaboration between Chugai and Rosa will provide Chugai a competitive research and development advantage across multiple therapeutic areas and throughout Chugai's R&D pipeline, delivering unique scientific insights and actionable program recommendations, reducing risk and addressing complex and consequential decisions inherent in drug development.

"Chugai strives to develop hand in hand with society through creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation," said Kimio Terao, Department Manager of the Clinical Pharmacology Department, Translational Research Division, in Chugai.

Rosa's agreement with Chugai further extends Rosa's position as the global market leader in PhysioPD Research, a Quantitative Systems Pharmacology (QSP) approach that translates biology into an interactive simulation platform representing physiology, disease, and intervention effects. It also reinforces the value that PhysioPD Research Platforms deliver through greater scientific insight and more informed drug discovery and development decisions.

"We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings," said Rosa Founder, Chairman, & CEO Ron Beaver, PhD. "Our Strategic Research Agreements are a particularly efficient means to achieve the benefits of PhysioPD Research on a portfolio-wide basis."

About Rosa
Rosa & Co was established in 2002 and is known worldwide for its PhysioPD™ Research Platforms which elucidate the connection between disease mechanisms, therapeutic interventions, and clinical outcomes. PhysioPD Research delivers credible scientific insights and actionable program impact that would be difficult or impossible to achieve with any other research approach.

Pharmaceutical, biotechnology, and consumer goods clients realize significant return on investment when using PhysioPD Research for identifying responder patient populations, selecting predictive biomarkers, prioritizing or repurposing compounds, and predicting clinical efficacy of new targets. With decades of experience, 100+ presentations and publications, and mature business processes Rosa works effectively in complex organizational and scientific settings, ultimately helping clients reduce the risk of unsuccessful clinical trials or product submissions across their entire portfolio.

For more information, visit http://www.rosaandco.com/chugai

About Chugai
Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Additional information is available on the internet at https://www.chugai-pharm.co.jp/english/.

 

Cision View original content:http://www.prnewswire.com/news-releases/rosa--co-announces-strategic-research-agreement-with-chugai-pharmaceutical-co-ltd-300809885.html

SOURCE Rosa & Co. LLC